Aptevo's CD3-engaging portfolio is anchored by mipletamig, a first-in-class CD123 x CD3 bispecific currently being evaluated in RAINIER, a Phase 1b/2 trial for frontline AML. In total, mipletamig has ...
The FDA has granted accelerated approval to Amgen’s tarlatamab (Imdelltra) for extensive-stage small-cell lung cancer (SCLC). This first-in-class DLL3 × CD3-targeted therapy expands the scope of ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback